Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $1.3 billion.

  • Collegium Pharmaceutical's Total Liabilities fell 487.95% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 487.95%. This contributed to the annual value of $1.4 billion for FY2024, which is 5136.45% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Total Liabilities stood at $1.3 billion for Q3 2025, which was down 487.95% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Total Liabilities peaked at $1.4 billion during Q4 2024, and registered a low of $460.7 million during Q2 2021.
  • Its 5-year average for Total Liabilities is $981.4 million, with a median of $1.0 billion in 2022.
  • Per our database at Business Quant, Collegium Pharmaceutical's Total Liabilities soared by 12748.7% in 2022 and then tumbled by 1740.21% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Total Liabilities (Quarter) stood at $489.1 million in 2021, then soared by 100.2% to $979.3 million in 2022, then decreased by 3.21% to $947.9 million in 2023, then soared by 51.36% to $1.4 billion in 2024, then decreased by 7.13% to $1.3 billion in 2025.
  • Its Total Liabilities was $1.3 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.4 billion in Q1 2025.